ASCENT-04
What it tests: Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC: PFS2
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.